Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case study of a 64-year-old woman with kerion celsi caused by Microsporum canis, treatment with the oral antifungal fosravuconazole resulted in symptom resolution without scarring or side effects over 12 weeks, suggesting its potential effectiveness for various dermatomycoses.

In a randomized phase 2b clinical trial, oral ritlecitinib significantly reduced facial vitiligo area scores in patients with active nonsegmental vitiligo compared to placebo, with a favorable safety profile observed over 48 weeks, suggesting its potential as an effective treatment option (Ezzedine et al., 2023).

This report discusses the use of intralesional cidofovir and suggests it might be a viable option for treating SCC due to its successful outcome without observed systemic toxicity in this case.

In this case report, isotretinoin treatment led to complete remission of folliculitis decalvans lesions in a 26-year-old male after a year and a half, despite the lack of certain histopathology images and control tests; the findings also suggest potential familial clustering needing further genetic investigation.

In this study, baricitinib 4 mg led to greater scalp, eyebrow, and eyelash hair regrowth in severe alopecia areata patients than baricitinib 2 mg at weeks 36 and 52.

In this study, patients with severe alopecia areata treated with baricitinib over 152 weeks experienced sustained patient-reported improvements in scalp, eyebrow, and eyelash hair regrowth, with higher responders observed in the 4mg dose group compared to the 2mg group.

In this study, baricitinib showed promising results in improving scalp, eyebrow, and eyelash hair loss in adults with severe and very severe alopecia areata over 52 weeks.

This narrative review reports that baricitinib, a first-generation JAK inhibitor, has shown effectiveness in treating alopecia areata and atopic dermatitis and holds promise for other chronic dermatoses, marking a significant advancement in dermatological immunotherapy according to the summarized findings.

Tretinoin gel is safe for sun exposure, but tacalcitol doesn't significantly improve non-segmental vitiligo.

This case report describes a 69-year-old woman who developed drug-induced acquired ichthyosis related to ponatinib therapy, which improved upon stopping the medication.

This study found that topical calcipotriol was significantly more effective than topical tacrolimus in promoting hair growth for alopecia areata patients, demonstrating 67% efficacy compared to 33% efficacy with tacrolimus over a 6-month period.

This source describes vitiligo as a chronic condition marked by the loss of skin pigmentation and discusses leukotrichia, a feature affecting 10% to 60% of cases, which arises from melanocyte loss in hair follicles and appears as well-defined white patches on the skin.

In this case study, an 11-year-old girl with a Cladosporium scalp infection showed significant improvement in hair growth and appearance after treatment with itraconazole.

In this case report, two female patients with refractory systemic lupus erythematosus showed significant improvement after treatment with the JAK inhibitor upadacitinib, indicating potential as a promising option for difficult cases, although further research is needed to confirm its broader safety and efficacy.

TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.

This review reports that innovative topical treatments for dermatologic conditions like acne and atopic dermatitis show minimal systemic absorption, indicating improved safety and tolerability compared to traditional therapies.

This study found that combining dermoscopy with reflectance confocal microscopy is more sensitive and specific than using either method alone for assessing vitiligo disease activity and treatment response. Additionally, specific characteristics observed via these techniques correlated with either good or poor treatment outcomes.

This study found that oral spironolactone improved certain biomarkers in central serous chorioretinopathy patients, but recurrence, especially in older patients, was relatively common.

A new food supplement was highly effective in curing hair loss in young men.

This study found that microneedling combined with calcipotriol plus betamethasone was more effective in treating vitiligo than microneedling with tacrolimus, particularly in difficult-to-treat areas.

In this study, increasing cases of allergic contact dermatitis in Bulgaria were linked to the use of natural products like propolis and marigold.

In this case series, three patients with advanced non-small cell lung cancer experienced severe skin eruptions and scarring alopecia after treatment with amivantamab, highlighting the critical need for prompt recognition and management of these adverse effects to minimize treatment interruptions.

This study found that approximately 85% of adults with severe alopecia areata who responded to baricitinib at 52 weeks maintained their improvement over a span of four years.

This review provides guidelines for physicians on using hormonal therapies, such as androgen receptor blockers and oral contraceptives, to treat hormonally related acne, but reports no new clinical findings.

This article discusses the potential of oral tofacitinib as a treatment for atopic dermatitis, alopecia areata, and vitiligo, without presenting new clinical results.

This article discusses the use of imiquimod as a treatment for actinic keratosis, basal cell carcinoma, and human papillomavirus warts, noting both its therapeutic benefits and common side effects such as local inflammation and flu-like symptoms.

The researchers reported that the antipsoriatic compounds 1,25-dihydroxy-vitamin D3 and calcipotriol thinned the living cell compartment in organotypic ORS cultures by accelerating the differentiation pathway rather than affecting proliferation.

In two phase 3 clinical trials, this study found that adults with severe alopecia areata receiving baricitinib experienced significant hair regrowth on the scalp, eyebrows, and eyelashes over 36 weeks compared to placebo, although longer-term data are needed to fully assess benefits and risks.

This review provides insights and guidelines for clinicians and patients on assessing the risks and benefits of ritlecitinib for adolescents with alopecia areata, emphasizing shared decision-making and management strategies.

This review outlines the practical use of reflectance confocal microscopy in dermatology, detailing its applications and considerations for diagnosing various skin conditions, but reports no new findings.